Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
~49 mi.
(Bellinzona,
Switzerland,
+150 more cities)
Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1921)
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
~49 mi.
(Bellinzona,
Switzerland,
+105 more cities)
Ospedale Regionale di Bellinzona e Valli ( Site 1407)
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
~49 mi.
(Bellinzona,
Switzerland,
+76 more cities)
Ospedale Regionale Bellinzona e Valli ( Site 2203)
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
~49 mi.
(Bellinzona,
Switzerland,
+15 more cities)
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
~63 mi.
(Ponderano,
Italy,
+383 more cities)
Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica